Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system ... with increased efficacy at higher doses (300 mg), and was more effective in females and IBS-C/IBS-M subtypes.

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership ...

Mounjaro is approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...